Zymeworks (NYSE:ZYME) Coverage Initiated by Analysts at Lifesci Capital

Equities researchers at Lifesci Capital assumed coverage on shares of Zymeworks (NYSE:ZYME - Get Free Report) in a note issued to investors on Tuesday,Benzinga reports. The brokerage set an "outperform" rating and a $30.00 price target on the stock. Lifesci Capital's target price points to a potential upside of 170.27% from the company's current price.

ZYME has been the subject of several other reports. Wells Fargo & Company raised their price objective on shares of Zymeworks from $12.00 to $14.00 and gave the stock an "equal weight" rating in a report on Thursday, December 19th. HC Wainwright lifted their price target on Zymeworks from $12.00 to $13.00 and gave the stock a "neutral" rating in a research note on Monday. Citigroup upped their price objective on Zymeworks from $18.00 to $19.00 and gave the company a "buy" rating in a research note on Friday. Finally, JPMorgan Chase & Co. upgraded Zymeworks from a "neutral" rating to an "overweight" rating and set a $18.00 target price for the company in a research report on Monday, December 16th. Two investment analysts have rated the stock with a hold rating, five have issued a buy rating and one has assigned a strong buy rating to the company. Based on data from MarketBeat.com, the stock currently has a consensus rating of "Moderate Buy" and an average target price of $21.00.

Zymeworks Stock Down 7.5 %

Shares of ZYME opened at $11.10 on Tuesday. The firm has a market cap of $772.30 million, a price-to-earnings ratio of -7.40 and a beta of 1.13. The business's 50 day moving average is $14.14 and its two-hundred day moving average is $13.66. Zymeworks has a 52-week low of $7.97 and a 52-week high of $17.70.

Insider Buying and Selling at Zymeworks

In other news, Director Ecor1 Capital, Llc purchased 204,098 shares of Zymeworks stock in a transaction dated Friday, January 10th. The stock was bought at an average price of $13.13 per share, with a total value of $2,679,806.74. Following the completion of the acquisition, the director now owns 15,411,078 shares in the company, valued at $202,347,454.14. The trade was a 1.34 % increase in their position. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website. Also, CEO Kenneth Galbraith sold 57,291 shares of the company's stock in a transaction dated Monday, January 6th. The stock was sold at an average price of $14.92, for a total transaction of $854,781.72. Following the transaction, the chief executive officer now owns 47,543 shares of the company's stock, valued at $709,341.56. This represents a 54.65 % decrease in their position. The disclosure for this sale can be found here. Over the last ninety days, insiders purchased 603,539 shares of company stock worth $8,384,708 and sold 89,601 shares worth $1,336,847. 1.92% of the stock is currently owned by insiders.

Institutional Trading of Zymeworks

Large investors have recently added to or reduced their stakes in the business. Polar Asset Management Partners Inc. bought a new position in shares of Zymeworks in the fourth quarter worth $527,000. Voloridge Investment Management LLC acquired a new stake in Zymeworks in the fourth quarter worth about $640,000. Point72 Asset Management L.P. grew its position in Zymeworks by 565.8% in the 4th quarter. Point72 Asset Management L.P. now owns 330,127 shares of the company's stock valued at $4,833,000 after buying an additional 280,544 shares in the last quarter. Nuveen Asset Management LLC increased its stake in Zymeworks by 0.4% during the 4th quarter. Nuveen Asset Management LLC now owns 207,023 shares of the company's stock valued at $3,031,000 after buying an additional 886 shares during the period. Finally, Deutsche Bank AG raised its position in shares of Zymeworks by 1.2% during the 4th quarter. Deutsche Bank AG now owns 1,546,772 shares of the company's stock worth $22,645,000 after buying an additional 17,849 shares in the last quarter. 92.89% of the stock is currently owned by institutional investors and hedge funds.

Zymeworks Company Profile

Zymeworks Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes biotherapeutics for the treatment of cancer. The company's lead product candidates include zanidatamab, a human epidermal growth factor receptor 2 (HER2) that is in Phase 1, Phase 2, and Phase 3 clinical trials, including certain ongoing pivotal clinical trials; and zanidatamab zovodotin, a HER2 -targeted antibody-drug conjugate that is in Phase 2 clinical trial for the treatment of advanced or metastatic HER2-expressing tumors.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.

Remove Ads